Fellowship · Dallas, TX
Sponsored by University of Texas Southwestern Medical Center
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 399 citations · Susan Iannaccone
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Nature medicine · 2022 · 263 citations · Susan Iannaccone
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Nature medicine · 2022 · 236 citations · Susan Iannaccone
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
JAMA neurology · 2024 · 94 citations · Benjamin Greenberg
Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
Annals of neurology · 2024 · 88 citations · Benjamin Greenberg
Acute flaccid myelitis: cause, diagnosis, and management.
Lancet (London, England) · 2021 · 133 citations ·
Pediatric neuromodulation for drug-resistant epilepsy: Survey of current practices, techniques, and outcomes across US epilepsy centers.
Epilepsia open · 2024 · 29 citations · Charuta Joshi
Anti-NMDA Receptor Autoimmune Encephalitis: Diagnosis and Management Strategies.
International journal of general medicine · 2023 · 61 citations · Cynthia Wang